Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur Rev Med Pharmacol Sci ; 16 Suppl 2: 2-7, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22655478

ABSTRACT

Pyogenic spondylodiscitis (PS) is an uncommon but important infection, that represents 3-5% of all cases of osteomyelitis. The annual incidence in Europe has been estimated to be from 0.4 to 2.4/100,000. A has been reported, with peaks at age less than 20 years and in the group aged 50-70 years. The incidence of PS seems to be increasing in the last years as a result of the higher life expectancy of older patients with chronic debilitating diseases, the rise in the prevalence of immunosuppressed patients, intravenous drug abuse, and the increase in spinal instrumentation and surgery. PS is in most cases a hematogenous infection. Staphylococcus aureus is the most frequent causative microorganism, accounting for about one half of the cases of PS. Gram-negative rods are causative agents in 7-33% of PS cases. Coagulase-negative staphylococci (CoNS) have been reported in 5-16% of cases. Staphylococcus epidermidis is often related to post-operative infections and intracardiac device-related bacteremia. Unremitting back pain, characteristically worsening during the night, is the most common presenting symptom, followed by fever that is present in about one half of the cases. The mortality of PS ranges from 0 to 11%. In a significant number of cases, recrudescence, residual neurological defects or persistent pain may occur.


Subject(s)
Discitis/diagnosis , Discitis/epidemiology , Intervertebral Disc , Osteomyelitis/diagnosis , Osteomyelitis/epidemiology , Aged , Bacteriological Techniques , Discitis/microbiology , Discitis/mortality , Discitis/therapy , Humans , Incidence , Intervertebral Disc/microbiology , Intervertebral Disc/pathology , Middle Aged , Osteomyelitis/microbiology , Osteomyelitis/mortality , Osteomyelitis/therapy , Predictive Value of Tests , Prognosis , Risk Assessment , Risk Factors , Young Adult
2.
Eur Rev Med Pharmacol Sci ; 16 Suppl 2: 35-49, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22655482

ABSTRACT

BACKGROUND: Pyogenic vertebral osteomyelitis (PVO) represents approximately 2-7% of all cases of osteomyelitis. The approach to the treatment of PVO may be conservative, which includes antibiotic therapy and orthopaedic treatment, or surgical. AIM: To overview conservative and surigical approaches to PVO. METHODS: A literature review was performed using the Pubmed database to identify studies published in the last 20 years, addressing the treatment of PVO. RESULTS: Empirical antibiotic treatment of PVO, while waiting for the results of cultures or in culture-negative cases, should include broad spectrum agents in association with agents active on Staphylococcus (S.) aureus. Based on local epidemiological data, antibiotics active on methicillin resistant S. aureus (MRSA) should be included. Once an organism has been identified, antibiotics should be initially administered intravenously but the optimal duration of antimicrobial therapy is unclear. Studies have reported that the incidence of treatment failure was higher when i.v. therapy was administered for less than 4 weeks. Rifampin is widely used in the combination therapy of PVO, but no controlled trials are available to define weather this approach is beneficial. Many PVO need a surgical treatment and can represent a real challenge for the orthopaedic surgeon. Anterior and posterior cervical, thoracic, lumbar approaches and the relatives surgical strategies are reported in this review. Moreover, recently the mininvasive posterior stabilization have been proposed as a efficient alternative to open surgery in elderly with severe comorbidities. Possible advantages and limitations of this technique are also reported. CONCLUSIONS: Further research is needed in order to define the optimal duration of antibiotic therapy, and the benefits and limitations of open or mini-invasive surgical techniques.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Discitis/therapy , Intervertebral Disc/surgery , Orthopedic Procedures , Osteomyelitis/therapy , Aged , Discitis/diagnosis , Discitis/microbiology , Discitis/surgery , Humans , Intervertebral Disc/microbiology , Male , Middle Aged , Osteomyelitis/diagnosis , Osteomyelitis/microbiology , Osteomyelitis/surgery , Treatment Outcome
3.
Eur Rev Med Pharmacol Sci ; 16 Suppl 2: 58-72, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22655484

ABSTRACT

BACKGROUND: Tuberculous spondylodiscitis (TS) is a rare but serious clinical condition which may lead to severe deformity and early or late neurological complications. AIM: To discuss certain aspects of the approach to TSs, focusing upon epidemiology, diagnosis, and treatment outcome. MATERIALS AND METHODS: For the purpose of this review, a literature search was performed using the Pubmed database through to 19th October 2011 to identify studies published in the last 20 years, concerned in epidemiological, clinical, diagnostic, and therapeutical aspects of TS in adults. Only studies drafted in English language and reporting case series of more than 20 patients have been included. RESULTS: TS has been reported to accounts for 1-5% of all TB cases, and for about 50% of the cases of articulo-skeletal TB infections. Despite the actual availability of more effective diagnostic tools, early recognition of TS remains difficult and a high index of suspicion is needed due to the chronic nature of the disease and its insidious and variable clinical presentation. A prompt diagnosis is required to improve long term outcome, and a microbiological confirmation is recommended to enable appropriate choice of anti-mycobacterial agents. Surgery has an important role in alleviating pain, correcting deformities and neurological impairment, and restoring function. CONCLUSIONS: Further studies are required to assess the appropriate duration of anti-microbial treatment, also in regarding of a combined surgical approach.


Subject(s)
Discitis/microbiology , Intervertebral Disc/microbiology , Mycobacterium tuberculosis/pathogenicity , Osteomyelitis/microbiology , Tuberculosis, Spinal/microbiology , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Bacteriological Techniques , Discitis/diagnosis , Discitis/epidemiology , Discitis/therapy , Female , Humans , Intervertebral Disc/surgery , Male , Middle Aged , Mycobacterium tuberculosis/isolation & purification , Orthopedic Procedures , Osteomyelitis/diagnosis , Osteomyelitis/epidemiology , Osteomyelitis/therapy , Predictive Value of Tests , Treatment Outcome , Tuberculosis, Spinal/diagnosis , Tuberculosis, Spinal/epidemiology , Tuberculosis, Spinal/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...